Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 57.00 331,070 09:18:04
Bid Price Offer Price High Price Low Price Open Price
56.00 58.00 57.00 56.00 56.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.31 -5.28 -4.30 79
Last Trade Time Trade Type Trade Size Trade Price Currency
16:02:23 O 25,000 56.50 GBX

Diurnal (DNL) Latest News (1)

More Diurnal News
Diurnal Investors    Diurnal Takeover Rumours

Diurnal (DNL) Discussions and Chat

Diurnal Forums and Chat

Date Time Title Posts
08/3/202122:10Diurnal Group plc3,673
04/8/202005:08Diurnal (MC Ј25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP404

Add a New Thread

Diurnal (DNL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-08 16:02:2456.225,3493,007.21O
2021-03-08 16:00:1256.2217,78810,000.41O
2021-03-08 14:28:0156.229,2355,191.92O
2021-03-08 14:25:5356.5050,00028,250.00O
2021-03-08 12:56:3156.5050,00028,250.00O
View all Diurnal trades in real-time

Diurnal (DNL) Top Chat Posts

Diurnal Daily Update: Diurnal Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DNL. The last closing price for Diurnal was 57p.
Diurnal Group Plc has a 4 week average price of 54.70p and a 12 week average price of 48.50p.
The 1 year high share price is 75p while the 1 year low share price is currently 21p.
There are currently 138,328,939 shares in issue and the average daily traded volume is 1,267,794 shares. The market capitalisation of Diurnal Group Plc is £78,847,495.23.
glasswala: Still so many sells subduing the share price. Am i missing some sort of signal which is indicating something opposite to what everyone is hoping for from DNL??
affc21: Thanks for that podcast Simon,Well worth listening to and may bring in some new investors. It would certainly help in getting some momentum behind the share price.Vadim Alexandre, Head of Healthcare at share price Angel, spoke about DNL being a binary bet, with risks to the downside, but the company was heavily skewed to the upside.That was my take from the podcast which may be biased seeing as I am a shareholder in the company. So please do your own research.
mufprat: Said it before will say it again. Revenues are the answer. A company can only go so far on potential. DNL appears to have reached the potential ceiling so once increasing revenue streams are reported the share price will break out. It's all coming together nicely. Chronocourt approvals will lead to rapid sales as the foundations are already in place of being out in place.
hennes ix: we need some fundamental input here and not the every day push and bash without facts. My question is here, may be for best, nobby or other: Chronocort is like Alkindi but for adults (my lay knowledge). You have the biggest restriction to get a medi to the market for kids, pediatrics. Why the EMA should not approve Chronocort for adults? Is it efficity? I don't like the share price development here, but actually no complaint, because there is much time in q1 until a decision and share price to grow. Is there any source for CHMP recommendation for chronocort positive or negative. Thank's in advance for an answer and sorry for possible mistakes in the formulation, cause I'm not a native speaker ...
frrinvest: Its hard enough to get one drug approval, but to get two approvals for a small pharma like DNL would be absolutely mind blowing if they get the green light for Choronocort. DNL have the global market with a little or no competition all to themselves. The share price will reflect this hopefully in the near to mid term. GLA!
hunsen: Last #DNL CHMP announcement for Alkindi saw a 21% share price increase, the final EMA approval saw another 18% increase, this was in 2017 when the share price was 200p plus. The difference now is that Chronocort will push DNL from revenue generating to profitability within the next two years. Opportunity for significant upside in the region of 220% (not adjusted for dilution)
hunsen: Glasswala, you comments are wrong and not qualified at all. “Confidence has gone from this share” – this is wrong, the company has rerated from the high 20’s, low 30’s to the high 40s, low 50s – an increase of 72% pre Alkindi FDA approval. Funds are increasing holdings and one individual fund manager is (mostly out) – it’s a “stock market” and it’s AIM. There currently is no momentum or volume, there is so much action elsewhere at the moment and there is not much to see here. “Directors prone to giving shares away at a discount” – this is wrong, the company needs funding because it is not yet profitable – you should have done your research before leaping into a share. The Directors have a choice of getting a loan (which attracts interest which must be paid to the lender BEFORE shareholders), OR Directors can go to shareholders and pay that interest in the form of a discount. Shareholders then have the choice to take part or not. As it happens, the 9% discount on the last placing was quite a premium to where the share currently sits – so the company did very well, and shareholders will hopefully be rewarded in time. The DNL share price has increased 72%, there is no reason for a further increase before the New Year. There may still be a small stock overhang from a large seller, when this clears the price may increase as MM struggle to buy shares. Positive news may also drive an increase – the next news will hopefully be approval of Chronocort. The Directors then need to start delivering on the business plan – so far, they have remained consistent in my view. ALB
74tom: And still Griffiths sells... The problem here, along with many other AIM small caps is lack of volume. One big holder decides to dump and the price gets taken to the cleaners. Comparing DNL with ETON is very interesting, in that they are two similar size small cap pharma's but trade on different exchanges. In the last 100 trading days starting on 13th July, DNL has total share volume of 49.5m, multiplying this by each days closing price we can estimate that around £28.2m has flowed through in this period. In the same period ETON has traded 46.6m shares, for a total value of around $348m (£261m). ETON started the 100 day period at $5.62 per share with 21m shares in issue, so had a market cap of $118m (£88m). DNL started the 100 day period at 30p per share with 122m shares in issue, so had a market cap of £36m. So both shares have been in a rising trend with positive news & both have also raised cash in the period, with ETON placing at $7 to raise $19m. Yet comparing share turnover vs market cap 100 days ago, ETON has traded nearly 3 x it's cap, whilst DNL has only traded 80%. This is the issue. Personally, whilst I'll keep an eye on DNL for bounce trade, I think the best way to benefit from Alkindi is to buy ETON shares. They have a pipeline of 8 other drugs & forecast FY22 sales of $74m... if they execute on that then their market cap could be $1b+. I also think there is a good chance they will in licence Chronocort too, particularly if they nail the Alkindi roll out. DNL meanwhile will continue to be handicapped by the lack of interest in UK small cap pharma, they would do far better moving to the US / anywhere other than AIM.
tarlok: For whatever reason someone really wants this share price kept low ( not sure it is the "big " seller ) time hopefully we will find out why ? was good a opportunity with good news yet its plain in short term MM are not going to move up share price...
tarlok: Absolutely !! think of how different things could have been if it was 70p ? confidence in share price, confidence for existing shareholders etc why did they have to sell issue at 60p when share price was 65/67p ...there now 15p lower anyway ...
Diurnal share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210309 01:33:44